Strengthening Our Future in Delft: Pierre-Yves Dalla-Libera Appointed Site Director
Rotterdam, Netherlands, 9 July 2025 - Centrient Pharmaceuticals*, the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals is pleased to announce the appointment of Pierre-Yves Dalla-Libera as Site Director for its Delft facility, effective 1 September 2025. Pierre-Yves succeeds Luigi De Martin, who will be pursuing new opportunities outside the company.
The Delft site holds unique strategic importance as the only antibiotic ingredient production facility in the Netherlands, playing a vital role in ensuring a stable, resilient supply of life-saving medicines across Europe and beyond. It is an integral part of Centrient’s commitment to safeguard essential antibiotics production and to lead the industry in the fight against antimicrobial resistance through innovative, sustainable manufacturing.
Pierre-Yves brings extensive leadership experience to this position. Since joining Centrient three years ago, he has held several key roles, including Head of External Supply Operations for Active Pharmaceutical Ingredients (ESO API), interim Site Head at Santa Perpetua, and Global Strategy Director for TechOps. Prior to Centrient, he held positions at Sanofi Pasteur and Centrale Lille, gaining broad expertise in strategic planning, project management, and international operations. A French national, Pierre-Yves holds a degree in IT, business, and engineering from Centrale Lille.
His appointment reflects Centrient’s strong commitment to developing in-house talent through its EDGE leadership development programme, which equips future leaders with the technical, operational, and strategic skills required for modern pharmaceutical manufacturing. This investment in mentoring and succession planning ensures a robust leadership pipeline to deliver on Centrient’s long-term ambitions.
Pierre-Yves assumes leadership at a decisive time, with the Delft site making major commitments in modern facilities and equipment to secure its independence and long-term resilience following DSM-firmenich’s exit from the yeast business. In close collaboration with local authorities and partners, Centrient is committed to reinforcing the site as a vital hub for sustainable growth and regional employment.
Vesna Kapelj, Chief Technical Operations Officer at Centrient, said: “Pierre-Yves’s appointment demonstrates our commitment to empowering our people to take on critical leadership roles that drive our strategy forward. I am confident that under his leadership, our Delft site will continue to deliver high-quality antibiotics, support Europe’s health resilience, and contribute to a healthier future for all. I would also like to thank Luigi De Martin for his contributions and wish him the very best in his next chapter.”
-----------------------------------------------------------------------------------------------------------------------
About Centrient Pharmaceuticals
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. We are a pharmaceutical company with a clear Purpose: to improve lives through innovative and sustainable manufacturing of medicines - saving the lives of millions of people around the world annually. Regarding our portfolio, we produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as finished dosage forms (FDFs). Centrient Pharmaceuticals is a Board Member of the AMR Industry Alliance and a long-time advocate for industry responsibility in manufacturing. For more information, please visit www.centrient.com, www.linkedin.com/company/centrient or contact Centrient Pharmaceuticals Global Communications and ESG Director, Neil Moorhouse. E-Mail: neil.moorhouse@centrient.com.
*( 1) “Centrient Pharmaceuticals”, “Centrient” in this content are sometimes used for convenience where references are made to Centrient International Pharmaceuticals B.V, and or one or more of its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Centrient Pharmaceuticals International B.V. and or one or more of its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. “Subsidiaries”, “Centrient subsidiaries” and “Centrient companies” as used in this content refer to entities over which Centrient Pharmaceuticals International B.V. either directly or indirectly has control. The term “Centrient interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Centrient Pharmaceuticals International B.V. in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.
